Federal Register #2026-19431

NIH Offers Licensing Opportunity for Preclinical Recombinant Minibody Technology

The National Institutes of Health (NIH), part of the Department of Health and Human Services, is offering government-owned inventions for licensing to advance public health through commercialization. - Government Buyer: - Department of Health and Human Services - National Institutes of Health (NIH) - National Heart, Lung, and Blood Institute (NHLBI) - Technology Available: - Recombinant bivalent single-chain variable fragment (scFV) minibody targeting the cMPL receptor on hematopoietic stem and progenitor cells (HSPCs) - Fused with truncated diphtheria toxin (DT390-biscFV(cMPL)) - Preclinical-stage, with in vivo animal data - Intellectual Property: - Multiple patent applications filed in the US, Europe, Israel, and China - Reference: HHS Ref. No.: E-188-2021-0 - Purpose and Benefits: - Designed to improve safety in conditioning regimens for HSPC transplantation, especially for leukemia patients - Aims to reduce reliance on cytotoxic chemotherapy and radiation - Opportunity Details: - NHLBI seeks parties for collaborative research or licensing - No commercial OEMs or vendors are named; NIH is the technology originator - Unique Requirements: - Focus on licensing and collaborative research for further development and commercialization - Technology is not yet commercially available; intended for partners with relevant expertise

Description

This notice announces that certain inventions owned by the U.S. Government are available for licensing to facilitate commercialization of federally-funded research for public health benefits. The highlighted technology involves a recombinant bivalent single-chain variable fragment minibody targeting the cMPL receptor on hematopoietic stem and progenitor cells, fused with a truncated diphtheria toxin, intended to improve safety in stem cell transplantation conditioning regimens. The technology is in the preclinical stage with in vivo animal data available and is offered for collaborative research and licensing through the National Heart, Lung, and Blood Institute.

View original listing